Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44154   clinical trials with a EudraCT protocol, of which   7326   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2022-000152-11
    Sponsor's Protocol Code Number:D3250R00107
    National Competent Authority:France - ANSM
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2023-02-09
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedFrance - ANSM
    A.2EudraCT number2022-000152-11
    A.3Full title of the trial
    BURAN: Effects of Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma using Functional Respiratory Imaging Parameters
    Étude BURAN : Effets du Benralizumab sur la dynamique des voies aériennes dans l’asthme sévère éosinophilique évalués à l’aide de paramètres d’imagerie respiratoire fonctionnelle
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma using Functional Respiratory Imaging
    BURAN: Benralizumab sur la dynamique des voies aériennesdans l’asthme hyperéosinophilique sévère, évalués à l'aide imagerie respiratoire fonctionnelle
    A.3.2Name or abbreviated title of the trial where available
    BURAN
    BURAN
    A.4.1Sponsor's protocol code numberD3250R00107
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAstraZeneca AB
    B.1.3.4CountrySweden
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAstraZeneca AB
    B.4.2CountrySweden
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAstraZeneca
    B.5.2Functional name of contact pointClinical Study Information Center
    B.5.3 Address:
    B.5.3.1Street Address1800 Concorde Pike
    B.5.3.2Town/ cityWilmington
    B.5.3.3Post codeDE 19803
    B.5.3.4CountryUnited States
    B.5.4Telephone number+1877240 9479
    B.5.6E-mailInformation.Center@astrazeneca.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name FASENRA™
    D.2.1.1.2Name of the Marketing Authorisation holderAstraZeneca AB
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Solution for injection in pre-filled syringe
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNBenralizumab
    D.3.9.3Other descriptive nameFASENRA , formerly MEDI-563
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number30
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Yes
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Asthma
    Asthme
    E.1.1.1Medical condition in easily understood language
    Asthma is a disease that makes breathing difficult as there is swelling of the air passages resulting in airway narrowing. In severe eosinophilic asthma, this is caused by eosinophils blood cells.
    L’asthme est une maladie qui rend la respiration difficile à cause d’un rétrécissement des voies aériennes, dû aux cellules sanguines éosinophiles, dans l’asthme hyperéosinophilique sévère.
    E.1.1.2Therapeutic area Diseases [C] - Respiratory Tract Diseases [C08]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10003553
    E.1.2Term Asthma
    E.1.2System Organ Class 10038738 - Respiratory, thoracic and mediastinal disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To describe the change from baseline in airway dynamics at week 13 following treatment with benralizumab, using siVaw (specific airway volume) measurements from trimmed airways.
    Décrire la modification, par rapport aux valeurs initiales, de la dynamique des voies respiratoires à la Semaine 13 après un traitement par benralizumab, en utilisant les mesures de volume spécifique des voies respiratoires (siVaw, specific airway volume) recueillies dans les voies respiratoires réduites.
    E.2.2Secondary objectives of the trial
    1. To describe the change from baseline (week 0) in airway dynamics at week 13 following treatment with benralizumab, as measured by FRI endpoints and mucus plugs scores, irrespective of patient characteristics.
    2. To describe the relationship between airway dynamics and conventional lung function measurements, cross-sectionally at baseline (week 0) and irrespective of patient characteristics.
    3. To describe the relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at week 13, after accounting for baseline measurements of conventional lung function.
    1. Décrire la modification, par rapport aux valeurs initiales, de la dynamique des voies respiratoires à la Semaine 13 après un traitement par benralizumab, mesurée par des critères d’évaluation IFR et des scores de bouchons de mucus, indépendamment des caractéristiques du patient.
    2. Décrire la relation entre la dynamique des voies respiratoires et les mesures de fonction pulmonaire classiques, transversalement (à la Semaine 0) et indépendamment des caractéristiques du patient.
    3. Décrire la relation entre les modifications observées à la Semaine 13, par rapport aux valeurs initiales (Semaine 0), de la dynamique des voies respiratoires et des mesures classiques de la fonction pulmonaire, après avoir pris en compte les mesures initiales de la fonction pulmonaire classique.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    - Participants who are diagnosed with asthma with documented reversibility post-bronchodilator or salbutamol either historical or at Visit 0 (V0).
    - Participants who have documented treatment with ICS and LABA for ≥ 3 months prior to V0 with or without oral corticosteroids and additional asthma controllers.
    - Participants who have documented peripheral blood eosinophil count ≥ 300 cells/μL at V0, or if Oral Corticosteroids (OCS)-dependent, a documented peripheral blood eosinophil count ≥ 150 cells/μL at V0.
    - Participants who have had a minimum of 2 exacerbations in the last 12 months prior to V0.
    - Participants who have pre-bronchodilator Forced Vital Capacity (FVC) < 65% of predicted at V0.
    - Participants who have pre-bronchodilator Forced Expiratory Volume in 1 second (FEV1) < 80% of predicted at V0.
    - Participants who have stable asthma regimen apart from the use of rescue medication including the use of any other asthma medication for at least 3 months prior to V0.
    - Participants who can perform acceptable and repeatable spirometry.
    - Participants who can withhold asthma maintenance medication for at least 12 hours prior to V0, 1 and 4 where spirometry and/or Computed Tomography (CT) scan procedures will be performed except for once-a-day dosage where 24 hours will be required.
    - Persons capable of becoming pregnant, who have a negative pregnancy test prior to administration of the investigational product (IP) and high-resolution CT scan and must agree to use a highly effective method of birth control (confirmed by the investigator – and consistent with local regulations regarding the methods of contraception for those participating in clinical studies) from randomization throughout the study duration and within 12 weeks after last dose of IP.
    - Asthme diagnostiqué avec réversibilité post-bronchodilatateur documentée ou salbutamol, soit d’après les antécédents ou à la Visite 0 (V0).
    - Traitement documenté par CSI et LABA pendant ≥ 3 mois avant la Visite 0 (V0), avec ou sans corticoïdes oraux et autres agents de contrôle de l’asthme.
    - Numération documentée des éosinophiles du sang périphérique ≥ 300 cellules/μl à la Visite 0 (V0), ou si le participant est CSO-dépendent, numération documentée des éosinophiles du sang périphérique ≥ 150 cellules/μl à la Visite 0 (V0).
    - Minimum de 2 exacerbations au cours des 12 derniers mois avant la Visite 0.
    - CVF pré-bronchodilatateur < 65 % de la valeur prédite à la Visite 0 (V0).
    - VEMS pré-bronchodilatateur < 80 % de la valeur prédite à la Visite 0 (V0).
    - Traitement de l’asthme stable hormis l’utilisation de médicaments de secours, y compris l’utilisation d’un autre médicament contre l’asthme pendant au moins 3 mois avant la Visite 0 (V0).
    - Capacité à effectuer une spirométrie acceptable et répétable.
    - Suspension possible du médicament d’entretien contre l’asthme pendant au moins 12 heures avant les Visites 0, 1 et 4 lorsque des évaluations spirométriques et/ou des examens TDM seront effectués, sauf pour la posologie monoquotidienne, qui nécessitera 24 heures de suspension.
    - Les personnes susceptibles d’être enceintes, ayant eu un test de grossesse négatif avant l’administration du médicament à l’étude (ME) et un examen TDM haute résolution, doivent consentir à l’utilisation d’un moyen de contraception efficace (confirmé par l’investigateur et compatible avec les réglementations locales relatives aux moyens de contraception pour les personnes participant à des études cliniques) à partir de la randomisation, pendant toute la durée de l’étude et dans les 12 semaines après la dernière dose du ME.
    E.4Principal exclusion criteria
    - Participants who are unstable or who experienced an exacerbation/infection in the 6 weeks before V0.
    - Participants with acute upper or lower airway infection in the 6 weeks before V0.
    - Participants diagnosed with clinically important pulmonary disease other than asthma, or participants who have ever been diagnosed with pulmonary or systemic disease, other than asthma that are associated with elevated peripheral eosinophil count.
    - Receipt of any biologic products for asthma within 4 months or 5 half-lives prior to V0 whichever is longer.
    - History or current use of chronic (i.e., > 4 weeks) immunosuppressive medication.
    - History of lung volume reduction surgery, lung resection, thermal bronchoplasty at any time before visit 0 (V0) or on active phase of pulmonary rehabilitation.
    - Participants with current malignancy or history of malignancy.
    - History of other clinically significant disease or abnormality.
    - Participants with positive Hepatitis B, C or HIV.
    - Participants with:
    Positive COVID-19 test at V0, COVID-19 disease within 6 weeks before V0 or History of severe COVID-19 disease at any time, defined by the need for Intensive Care Unit stay or Mechanical Ventilation (invasive or non-invasive).
    - Asthme instable ou survenue d’une exacerbation/infection dans les 6 semaines avant la Visite 0 (V0).
    - Infection aiguë des voies respiratoires supérieures ou inférieures dans les 6 semaines avant la Visite 0 (V0).
    - Diagnostic de pathologie pulmonaire cliniquement importante autre que l’asthme ou diagnostic de pathologie pulmonaire ou systémique autre que l’asthme, qui est associée à une numération élevée des éosinophiles périphériques.
    - Traitement pas agents biologiques contre l’asthme dans les 4 mois ou 5 demi-vies avant la Visite 0 (V0), selon la période la plus longue.
    - Antécédents ou utilisation chronique (c’est-à-dire > 4 semaines) en cours de médicaments immunosuppresseurs.
    - Antécédents de chirurgie de réduction du volume pulmonaire, de résection pulmonaire, de bronchoplastie thermique à tout moment avant la Visite 0 (V0) ou sous phase active de réadaptation pulmonaire.
    - Cancer actif ou antécédents de cancer.
    - Antécédent d’une autre pathologie ou anomalie cliniquement significative
    - Résultat positif d’une hépatite B, C ou VIH.
    - Présence de : résultat positif au test de dépistage de la COVID-19 à la Visite 0 (V0), atteinte COVID-19 dans les 6 semaines avant la Visite 0 (V0) ou antécédents de COVID-19 sévère à tout moment, défini par le besoin d’un séjour en unité de soins intensifs ou la nécessité d’une ventilation mécanique (invasive ou non-invasive).
    E.5 End points
    E.5.1Primary end point(s)
    Unadjusted within subject difference in siVaw (specific airway volume) measured at TLC, calculated as the mean percent change from baseline (week 0) at week 13 (± 5 days).
    Différence intra-patient non ajustée de siVaw (volume spécifique des voies respiratoires) mesuré à CPT, calculé sous forme de changement moyen en pourcentage par rapport aux valeurs initiales (Semaine 0) à la Semaine 13 (± 5 jours).
    E.5.1.1Timepoint(s) of evaluation of this end point
    baseline (week 0)
    week 13 (± 5 days)
    inclusion (semaine 0)
    semaine 13 (± 5 jours)
    E.5.2Secondary end point(s)
    1. Unadjusted within subject difference in iVlung, iVlobe, iVaww, air trapping, iRaw, mucus plugs score, BVX, IAD, ventilation mapping and ventilation/perfusion mapping, comparing baseline (week 0) to week 13 (± 5 days).
    2. Correlation between imaging endpoints [FRI endpoints (siVaw, iVlung, iVlobe, iVaww, air trapping, iRaw, BVX, IAD, ventilation mapping and ventilation/perfusion mapping) and mucus plugs score] and pre-bronchodilator forced expiratory volume in 1 second (pre-BD FEV1) at baseline (week 0).
    Correlation between imaging endpoints [FRI endpoints and mucus plugs score] and pre-bronchodilator forced vital capacity (pre-BD FVC) at baseline (week 0).
    Scatter plots of FRI endpoints and mucus plugs score versus conventional lung function measures (pre-BD FEV1 and pre-BD FVC) at baseline (week 0).
    Estimated increases in FRI endpoints and mucus plugs score for every one percent increase in pre-BD FEV1 and pre-BD FVC at baseline (week 0).
    3. Correlation between the change from baseline (week 0) in imaging endpoints [FRI endpoints and mucus plugs score] at week 13 and the change from baseline (week 0) in pre-BD FEV1 at week 13 (± 5 days), overall and within subgroups conditional on the baseline value of pre-BD FEV1.
    Correlation between the change from baseline (week 0) in imaging endpoints [FRI endpoints and mucus plugs score] at week 13 and the change from baseline (week 0) in pre-BD FVC at week 13 (± 5 days), overall and within subgroups conditional on the baseline value of pre-BD FVC.
    Scatter plots of changes from baseline (week 0) in FRI endpoints and mucus plugs score at week 13 vs. changes from baseline (week 0) in conventional lung function measures (pre-BD FEV1 and pre-BD FVC) at week 13.
    Estimated change over time [week 13 vs. baseline (week 0)] in FRI endpoints and mucus plugs score, with and without adjustment for conventional lung function measures (pre-BD FEV1 and pre-BD FVC).
    1. Différence intra-patient non ajustée de iVpoumon, iVlobe, iVaww, piégeage de l’air, iRaw, score de bouchons de mucus, BVX, IAD, cartographie de la ventilation et de la ventilation/perfusion, entre l’inclusion (Semaine 0) et la Semaine 13 (± 5 jours).
    2. Corrélation entre les critères d’évaluation d’imagerie [critères d’évaluation IFR (siVaw, iVpoumon, iVlobe, iVaww, piégeage de l’air, iRaw, BVX, IAD, cartographie de ventilation et de ventilation/perfusion) et score de bouchon de mucus] et le volume expiratoire maximum seconde avant bronchodilatateur (VEMS pré-BD) à la Semaine 0.
    Corrélation entre les critères d’évaluation d’imagerie [critères d’évaluation IFR et score de bouchon de mucus] et la capacité vitale forcée avant bronchodilatateur (CVF pré-BD) à la Semaine 0.
    Diagrammes dispersés de critères d’évaluation IFR et score de bouchon de mucus par rapport aux mesures de fonction pulmonaire classiques (VEMS pré-BD et CVF pré-BD) à la Semaine 0.
    Augmentations estimées des critères d’évaluation IFR et score de bouchon de mucus pour chaque association d’1 % entre VEMS pré-BD et CVF pré-BD à la Semaine 0.
    3. Corrélation entre la modification des critères d’évaluation d’imagerie [critères d’évaluation IFR et score de bouchon de mucus] à la Semaine 13 par rapport à la Semaine 0 et la modification de VEMS pré-BD à la Semaine 13 (± 5 jours), par rapport à la Semaine 0, globalement et au sein de sous-groupes en fonction de la valeur initiale de VEMS pré-BD.
    Corrélation entre la modification des critères d’évaluation d’imagerie [critères d’évaluation IFR et score de bouchon de mucus] à la Semaine 13 par rapport à la Semaine 0 et la modification de CVF pré-BD à la Semaine 13 (± 5 jours), par rapport à la Semaine 0, globalement et au sein de sous-groupes en fonction de la valeur initiale de CVF pré-BD.
    Diagrammes dispersés des modifications des critères d’évaluation IFR et score de bouchon de mucus observés à la Semaine 13 par rapport à la Semaine 0 comparativement aux modifications observées à la Semaine 13, par rapport à la semaine 0, des mesures de fonction pulmonaire classiques (VEMS pré-BD et CVF pré-BD).
    Modification estimée dans le temps (Semaine 13 vs. Semaine 0) des critères d’évaluation d’imagerie [critères d’évaluation IFR et score de bouchon de mucus, avec ou sans ajustement par rapport aux mesures classiques de la fonction pulmonaire (VEMS pré-BD et CVF pré-BD).
    E.5.2.1Timepoint(s) of evaluation of this end point
    1. Comparing baseline (week 0) to week 13 (± 5 days)
    2. At baseline (week 0)
    3. Comparing baseline (week 0) to week 13 (± 5 days)
    1. Comparaison de l’inclusion (semaine 0) à la semaine 13 (± 5 jours)
    2. A l’inclusion (semaine 0)
    3. Comparaison de l’inclusion (semaine 0) à la semaine 13 (± 5 jours)
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety No
    E.6.5Efficacy No
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) Yes
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    An interventional single group, open-label, uncontrolled, prospective, multicenter clinical trial.
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA17
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    United States
    France
    Spain
    Belgium
    Portugal
    United Kingdom
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of the study is defined as the date of the last expected visit/contact of the last participant undergoing the study.
    La fin d’étude est définie comme étant la date de la dernière visite / contact du dernier participant à l’étude
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days15
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months5
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 179
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 20
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state20
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 88
    F.4.2.2In the whole clinical trial 199
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Aucun
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2023-02-06
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2023-01-13
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2024-07-19
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA